U.S. Markets open in 7 hrs 3 mins

Aurinia Pharmaceuticals Inc. (ISA.TO)

. Currency in USD
Add to watchlist

Aurinia Pharmaceuticals Inc.

4464 Markham Street
Suite 1203
Victoria, BC V8Z 7X8

Full Time Employees15

Key Executives

Mr. Charles A. Rowland Jr., CPA, MBAChief Exec. Officer, Pres and Director43.31kN/A58
Mr. Michael R. MartinCo-Founder and Chief Operating Officer292.64kN/AN/A
Mr. Dennis Bourgeault C.A.Chief Financial Officer and Sec.272.46kN/AN/A
Mr. Neil Solomons M.D.Chief Medical Officer336.08kN/AN/A
Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C)VP of Clinical Affairs258.12kN/AN/A
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in .


Aurinia Pharmaceuticals Inc., a clinical stage pharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada. The company’s lead drug candidate is Voclosporin, a calcineurin inhibitor, which is in Phase IIb clinical trial for the treatment of lupus nephritis. It has a collaboration agreement with Paladin Labs Inc. to maintain the patent portfolio for Voclosporin in Canada, South Africa, and Israel; and development, distribution, and license agreement with 3SBio, Inc. for Voclosporin in China, Hong Kong, and Taiwan. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Corporate Governance

Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.